Tag Archives: Sales

Guangdong Launches Province‑Wide Survey on “Three Entry” Channels for Centralized Drug Procurement – Questionnaire Open to Primary, Private and Retail Healthcare Outlets Until 30 Sep 2026

Leave a reply

Guangzhou, China – 04 Sep 2026 – The Guangdong Provincial Drug Trading Center announced a special province‑wide survey targeting all medical institutions participating in the “Three Entry” (三进) channels for centrally procured drugs — grassroots public healthcare providers, medical‑insurance‑designated private institutions, and designated retail pharmacies — to gather data on procurement status, demand forecasts, supplier relationships, and financial‑service needs ahead of the program’s full rollout.

Policy Milestone

ItemDetail
Issuing AuthorityGuangdong Provincial Drug Trading Center
Policy BasisNotice of the Guangdong Provincial Healthcare Security Administration on Promoting the Entry of Centrally Procured Drugs into Grassroots Medical Institutions, Private Medical Institutions and Retail Pharmacies (Yue Yi Bao Han [2025] No. 208)
Initiative“Three Entry” (三进) program — bringing volume‑based procurement (VBP) drugs to grassroots, private and retail channels
Notice Date4 Sep 2026
Submission Deadline30 Sep 2026
Filing MethodOnline questionnaire via QR code in the announcement — completed by the institution head or procurement lead
Support ChannelsHotline 020‑38302291; WeChat 19102021272 (weekdays 8:30–12:00, 14:00–17:30)

Survey Scope & Coverage

  • Public Grassroots Institutions: Township health centers, eligible community health service centers/stations, village clinics, and comparable primary‑care providers legally established and in normal operation within Guangdong.
  • Private Medical Institutions: Facilities designated under the medical‑insurance system.
  • Retail Pharmacies: Medical‑insurance‑designated drugstores, including both standalone and chain pharmacies.
  • Data Collected: Current procurement practices, procurement demand forecasts, existing procurement relationships, and financial‑service needs across all three channels.

Participation & Data Use

  • Filing Obligation: Institutions are asked to complete the Guangdong Province Centralized Drug Procurement “Three Entry” Project Questionnaire truthfully and accurately, reflecting actual operating conditions.
  • Purpose Limitation: Submitted information will be used only to optimize the provincial platform’s implementation plan for the “Three Entry” program, improve the procurement and supply‑chain service system, and deliver precision matchmaking services between channels and suppliers.
  • Deadline Discipline: The questionnaire closes on 30 Sep 2026; no extensions were mentioned in the notice.

Market Impact & Outlook

  • Extending VBP Beyond Public Hospitals: The “Three Entry” program pushes centrally procured, price‑compressed drugs down into primary care, private clinics, and retail pharmacies — significantly widening the reachable market for winning bidders in national and Guangdong provincial procurement rounds.
  • Data‑Driven Rollout: By first mapping demand forecasts and supply relationships channel‑by‑channel, Guangdong is signaling a precision‑implementation approach rather than a blanket mandate — survey results will likely shape distribution rules, platform workflows, and possibly channel‑specific financing support.
  • Strategic Signal for Suppliers and Distributors: Pharmaceutical manufacturers and distributors should treat the 30 Sep deadline as an early‑warning indicator: institutions that participate will be better positioned in subsequent matchmaking, and the survey footprint previews where VBP drug flow will be steered next.
  • Retail Channel Watch: Inclusion of chain and standalone pharmacies aligns with the national healthcare‑security agenda of routing VBP savings to outpatient and OTC‑adjacent settings — a structural shift for retail drug pricing in China’s largest provincial pharmaceutical market.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation timeline, survey outcomes, and channel‑expansion plans of Guangdong’s “Three Entry” program for centrally procured drugs. Actual results may differ due to risks including participation rates, subsequent policy directives from provincial healthcare‑security authorities, supply‑chain capacity, and platform execution.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2096765545348075520

Policy Analysis and Guidance: Guangdong Province’s Volume-Based Drug Procurement Initiative

Leave a reply

Guangdong Province’s Drug Exchange Center has issued a notice outlining the implementation details of the centralized volume-based procurement initiative for medications such as Apixaban tablets. This policy, effective from April 1, 2025, to December 31, 2025, aims to streamline drug procurement processes, enhance supply chain stability, and ensure quality assurance across healthcare institutions.

Key Policy Measures

  1. Tripartite Contract Signing
    • Process: Medical institutions must use CA certificates to log into Guangdong’s tender and procurement subsystem to initiate tripartite contracts. Detailed operational guidance is available on the official website.
    • Timeline: Contracts must be completed promptly after initiation by medical institutions, with drug manufacturers and distributors required to log in and finalize agreements without delay.
  2. Quality and Supply Responsibility
    • Accountability: Drug manufacturers are designated as the primary responsible parties for ensuring the quality and timely delivery of medications. They must guarantee coverage of all participating healthcare institutions across the province.
    • Compliance: Selected manufacturers must adhere to agreed-upon procurement volumes and ensure uninterrupted supply chains.
  3. Procurement Volume Negotiation
    • Flexibility: For designated social healthcare institutions, procurement volumes will be determined through negotiations between supply and demand parties, allowing for tailored agreements.

Policy Orientation and Industry Implications
This initiative reflects Guangdong’s strategic focus on:

  • Cost Efficiency: Reducing drug prices through centralized procurement while maintaining quality standards.
  • Supply Chain Integrity: Ensuring uninterrupted medication supply to healthcare facilities across the province.
  • Transparency: Promoting clear contractual agreements and accountability mechanisms.

Conclusion
Guangdong’s volume-based procurement framework sets a benchmark for regional drug management, emphasizing efficiency, quality, and accessibility. Stakeholders, including manufacturers, distributors, and healthcare providers, should align their operations with these guidelines to optimize compliance and patient outcomes.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1906642648857317376

Policy Analysis and Guidance: Guangdong Province’s Ninth Batch of National Centralized Drug Procurement Renewal

Leave a reply

Guangdong Province’s Drug Exchange Center has issued a notice regarding the renewal of the ninth batch of national centralized drug procurement for the second procurement year, effective from March 30, 2025, to March 29, 2026. This policy aims to ensure the continuity of drug supply, maintain quality standards, and streamline procurement processes across healthcare institutions.

Key Policy Measures

  1. Viewing Contracted Procurement Volumes
    • Process: Medical institutions and selected enterprises can use CA certificates to log into Guangdong’s tender and procurement subsystem to view contracted procurement volumes. This transparency helps in planning and managing drug distribution efficiently.
  2. Tripartite Contract Signing
    • Procedure: Medical institutions must initiate tripartite contracts through the subsystem, with detailed operational guidance available on the official website. Timely contract completion by all parties is crucial to ensure smooth implementation.
  3. Quality and Supply Assurance
    • Responsibility: Drug manufacturers are held accountable for the quality and timely supply of medications. They must ensure coverage across all participating healthcare institutions in the province, emphasizing reliability in the supply chain.

Policy Orientation and Industry Implications
The renewal initiative underscores Guangdong’s commitment to:

  • Supply Stability: Ensuring uninterrupted drug supply to healthcare facilities.
  • Quality Control: Maintaining high standards for drug quality through clear accountability.
  • Efficiency: Streamlining procurement processes to enhance operational effectiveness.

Conclusion
Guangdong’s approach to centralized drug procurement renewal sets a precedent for regional pharmaceutical management, emphasizing reliability, quality, and efficiency. Stakeholders should adhere to these guidelines to optimize compliance and ensure patient access to essential medications.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1905839740230307840